ROKIT America, Inc. (RKAM)
ROKIT America will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet

Company Description

ROKIT America is committed to extending human healthspan and enhancing quality of life in an aging society through its proprietary Reverse Aging Product which is intended to support cellular health and aging-related biological processes at the molecular level, and its artificial intelligence hyper-personalized Organ Regeneration Platform, a proprietary technology developed by our parent company, ROKIT Healthcare, which is intended to provide regenerative medicine solutions in the Americas.

Since its founding in 2019, the Company has focused on the research and development of dietary supplements centered around β-Nicotinamide Mononucleotide (“NMN”).

We have launched a range of NMN-based products into global markets, including the United States. Our flagship product line, ROKIT AMERICA NMN, combines NMN with pterostilbene, a naturally occurring antioxidant.

ROKIT America, Inc.
Country United States
Founded 2019
Industry Packaged Foods
Sector Consumer Staples
CEO Seok Hwan You

Contact Details

Address:
3435 Wilshire Blvd, Suite 2925
Los Angeles, CA 90010
United States
Phone (678) 861-0046
Website rokitamerica.co.kr

Stock Details

Ticker Symbol RKAM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0002087716
Employer ID 38-4124442
SIC Code 2834

Key Executives

Name Position
Seok Hwan You Chief Executive Officer and Chairman of the Board of Directors
Ha Young Kim Chief Financial Officer and Director
Seong Mo Jee Chief Strategy Officer
Min Gu Lee Chief Medical Officer
Won Kyung Choi Chief Technology Officer
Woo Young Kim Chief Operation Officer
Min Kyoung Choi Chief Legal Officer

Latest SEC Filings

Date Type Title
Apr 15, 2026 S-1 General form for registration of securities under the Securities Act of 1933
Apr 2, 2026 DRS/A [Amend] [Cover] Draft Registration Statement
Mar 11, 2026 DRS/A [Amend] [Cover] Draft Registration Statement
Jan 16, 2026 DRS/A [Amend] [Cover] Draft Registration Statement
Oct 2, 2025 DRS [Cover] Draft Registration Statement